Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.

Connors, Joseph M.; Klimo, Paul; Adams, Grenfell; Burns, Bruce F.; Cooper, Ian; Meyer, Ralph M.; O’Reilly, Susan E.; Pater, Joseph L.; Quirt, Ian; Sadura, Anna; Shustik, Chaim; Skillings, Jamey; Sutcliffe, Simon; Verma, Shailendra; Yoshida, Sam; Zee, Benny

doi:10.1200/jco.1997.15.4.1638

Cited by 146 publications

(61 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4] However, the outcome of patients for whom initial induction chemotherapy fails is poor. 5,6 Despite a number of randomized controlled trials of primary therapy, very few prospective studies have assessed the outcomes of second-line treatments in patients with HL and thus, approaches in this setting are heterogeneous.…”

Section: Introductionmentioning

confidence: 99%

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

Puig¹,

Pintilie²,

Seshadri³

et al. 2010

Haematologica

View full text Add to dashboard Cite

BackgroundThe use of high-dose chemotherapy and autologous stem-cell transplantation in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials but its benefit in patients with primary refractory disease is less clear. Aiming to shed light on this issue, we analyzed and compared the outcomes of patients with relapsed or refractory Hodgkin's lymphoma treated with second-line chemotherapy and planned autologous stem-cell transplantation. Design and MethodsWe retrospectively analyzed data on 157 consecutive patients with Hodgkin's lymphoma referred to our institution for consideration of autologous stem-cell transplantation between 1999 and 2006. Of those, 73 met the definition of having primary refractory disease, ie. progressive disease during first line chemotherapy or within 3 months of completion of the treatment. Those patients achieving complete remission, partial remission and stable disease with symptomatic improvement after two or three cycles of salvage chemotherapy proceeded to stem cell mobilization and autologous transplantation. ResultsFrom first relapse/progression, the 3-year overall survival was 76% (95% CI: 66%-89%) for the refractory cohort and 91% (95% CI: 84%-98%) for the relapsed cohort (P=0.034); the overall response rate to second-line chemotherapy was 51% and 83% (P<0.0001), respectively. Threeyear progression-free survival post-transplant was 49% in refractory patients and 67% in relapsed patients (P=0.21); overall survival was 75% and 91% (P=0.097), respectively. ConclusionsUsing the group with relapsed disease as a reference, we can conclude that the subset of patients with chemosensitive primary refractory Hodgkin's lymphoma do benefit from autologous stem-cell transplantation.Key words: Hodgkin's lymphoma, transplantation, refractory.Citation: Puig N, Pintilie M, Seshadri T, al-Farsi K, Nagy T, Franke N, Tsang R, Keating A, Crump M, and Kuruvilla J. Different

show abstract

Section: Introductionmentioning

confidence: 99%

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

Puig¹,

Pintilie²,

Seshadri³

et al. 2010

Haematologica

View full text Add to dashboard Cite

show abstract

“…With 8000 new cases annually diagnosed in the U.S., greater than 75% of these patients will survive disease-free for more than 5 years, with most cured. [1][2][3] Patients not achieving complete remission (CR) at first-line treatment or who experience recurrence after CR are often salvaged with cytoreductive chemotherapy followed by high-dose chemotherapy supported by autologous stem cell transplantation (ASCT), inducing long-term disease-free survival in chemosensitive patients assessed on clinical, radiologic, and pathologic criteria. [4][5][6][7][8][9] Most patients who develop a recurrence after ASCT will die of their disease.…”

mentioning

confidence: 99%

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma

Jabbour

Hosing

Ayers

et al. 2007

Cancer

139

View full text Add to dashboard Cite

In speech production research using real‐time magnetic resonance imaging (MRI), the analysis of articulatory dynamics is performed retrospectively. A flexible selection of temporal resolution is highly desirable because of natural variations in speech rate and variations in the speed of different articulators. The purpose of the study is to demonstrate a first application of golden‐ratio spiral temporal view order to real‐time speech MRI and investigate its performance by comparison with conventional bit‐reversed temporal view order. Golden‐ratio view order proved to be more effective at capturing the dynamics of rapid tongue tip motion. A method for automated blockwise selection of temporal resolution is presented that enables the synthesis of a single video from multiple temporal resolution videos and potentially facilitates subsequent vocal tract shape analysis. Magn Reson Med, 2011. © 2010 Wiley‐Liss, Inc.

show abstract

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] Once patients relapse after initial therapy, however, conventionaldose chemotherapy regimens usually fail to provide durable complete remissions. [17][18][19][20][21][22][23][24] In the series with the longest follow-up, Longo and associates 17 reported that although 93% of relapsing patients could be re-induced into a second complete remission, only 17% of these remissions were durable.…”

mentioning

confidence: 99%

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)

Lazarus

Loberiza

Zhang

et al. 2001

Bone Marrow Transplant

109

View full text Add to dashboard Cite

Summary:Although patients with relapsed Hodgkin's disease have a poor prognosis with conventional therapies, high-dose chemotherapy and autologous hematopoietic stem cell transplantation (autotransplantation) may provide long-term progression-free survival. We reviewed data from the Autologous Blood and Marrow Transplant Registry (ABMTR) to determine relapse, disease-free survival, overall survival, and prognostic factors in this group of patients. Detailed records from the ABMTR on 414 patients with Hodgkin's disease in first relapse (n = 295) or second complete remission (CR) (n = 119) receiving an autotransplant from 1989 to 1995 were reviewed. Median age was 29 (range, 7-64) years. Median time from diagnosis to relapse was 18 (range, 6-219) months; median time from relapse to transplant was 5 (range, Ͻ1-215) months. Most patients received high-dose chemotherapy without total body irradiation for conditioning (n = 370). The most frequently used high-dose regimen was cyclophosphamide, BCNU, VP-16 (CBV) (n = 240). The graft consisted of bone marrow (n = 246), blood stem cells (n = 112), or both (n = 56).

show abstract

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.

Abstract: MOPP/ABV hybrid and alternating MOPP/ABVD regimens are equally effective for patients with advanced Hodgkin's disease.

Cited by 146 publications

References 14 publications

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)

Contact Info

Product

Resources

About